As over 20 drugs with a combined annual sales value of $250 billion are set to go off-patent, Indian companies have been exhorted to step in with generic and biosimilar versions.
Noting that a massive market opportunity awaits generic drug manufacturers, the Indian government is encouraging domestic pharma majors to seize the opportunity in a global market seeking economical solutions by manufacturing affordable alternatives, reports The Pharma Letter’s India correspondent.
A study for the Department of Pharmaceuticals study has revealed that by 2030, patents for 24 major blockbuster drugs, including global top-sellers like Humira (adalimumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Ibrance (palbociclib) and Symbicort (budesonide) will expire, unleashing a market valued at over $250 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze